HELSINGBORG, Sweden, April 15 /PRNewswire/ -- NOLabs AB, the Swedish medtech company focusing on developing innovative Nitric Oxide-containing medical devices, today reported that it has achieved another important milestone in the development of a new preventive therapy against urinary tract infection, UTI.
In experiments performed at the Karolinska University Hospital in Sweden, researchers showed that technology developed by NOLabs AB proved to have a high effectiveness in killing pathogens, typically for those causing UTI including an aggressive strain of E. coli. Millions of patients annually acquire UTI while being hospitalized for treatment of other diseases. Preventing such infection has the potential to dramatically reduce the amount of antibiotics used as well as improving quality of life for a large number of hospitalized patients.
Goran Beijer, CEO of NOLabs says; "We are happy to have taken another important step in developing products that have a huge potential to prevent millions of UTI cases globally every year. The anti-microbial effect of NO will be essential in a range of innovative products that prevent and/or treat infection. We expect to have the first products on the market in early 2009."
Professor Peter Wiklund, Karolinska University says; "This new technology has a huge potential to reduce the usage of Antibiotics and thereby the risk of antibiotic resistance as well as reducing the risk of urosepsis, the severest and potentially lethal consequence of UTI."
NOLabs is developing products that will prevent catheter related urinary tract infections, products that will be effective on reducing neuropathic pain and wound care products with an anti-bacterial effect.
NOLabs is a Swedish bio-medtech company focusing on the development and marketing of Nitric Oxide-containing medical devices for various medical applications. Nitric Oxide is a natural substance, produced by the human body controlling vaso-regulation and as part of its protection against pathogens. In particular, NOLabs focuses on developing effective Nitric Oxide based products and therapies that prevent infection and provide pain relief for millions of patients suffering from diabetes-related complications such as chronic wounds and neuropathic pain. Another focus area is the prevention and treatment of urinary tract infections. NOLabs has developed innovative, cost efficient and highly effective technologies that have a significant potential to address serious health issues that impact the lives of over 100 million people.
SOURCE NOLabs AB